Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03808922 · ClinicalTrials.gov registry record · Phase 3

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

A Phase 3 study of COVID-19 and Lower Respiratory Tract Infection, sponsored by Ansun Biopharma.

Recruiting
Registry status
Phase 3
Development phase
274
Enrollment target
20
Study locations

NCT03808922 is a Phase 3 study of COVID-19 and Lower Respiratory Tract Infection that is actively recruiting participants, run by Ansun Biopharma. The registered enrollment target is 274 participants, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03808922, a Phase 3 study of COVID-19 and Lower Respiratory Tract Infection, is actively recruiting participants, sponsored by Ansun Biopharma.

RECRUITING
Registry status
Phase 3
Development phase
274 participants
Enrollment target
20
Study locations

Study Summary

This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.

Conditions Studied

COVID-19 Lower Respiratory Tract Infection Immunocompromised Parainfluenza

Interventions

  • DRUG Placebo
  • DRUG DAS181
  • DRUG DAS181 COVID-19
  • DRUG DAS181 OL

Study Locations (20)

California

  • City of Hope cancer Center - Duarte
  • UCLA - Los Angeles
  • University of California Davis Health System - Sacramento
  • University of California San Diego Medical Center - San Diego

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
  • University of Chicago - Chicago
  • Loyola University Medical Center - Maywood

Florida

  • Sylvester Comprehensive Cancer Center, University of Miami Health System - Miami
  • Houston Methodist Hospital - Tampa

Maryland

  • University of Maryland - Baltimore
  • The Johns Hopkins Hospital - Baltimore

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

Colorado

  • Children's Hospital Colorado - Aurora

Iowa

  • University of Iowa Health Care - Iowa City

Kansas

  • University of Kansas Medical Center - Fairway

Trial Details

FieldValue
Enrollment Target 274 participants
Start Date 2019-05-23
Est. Completion 2025-08-31
Phase Phase 3

Sponsor

Ansun Biopharma

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03808922

The ClinicalTrials.gov registry entry for NCT03808922 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Ansun Biopharma, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT03808922 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Illinois, Florida.

Frequently Asked Questions

What is clinical trial NCT03808922 about?

NCT03808922 is a clinical study titled "Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study". This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.

What is the current status of trial NCT03808922?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 274 participants. The study started on 2019-05-23. Estimated completion is 2025-08-31.

What conditions does trial NCT03808922 study?

This clinical trial studies the following conditions: COVID-19, Lower Respiratory Tract Infection, Immunocompromised, Parainfluenza.

What interventions are being tested in trial NCT03808922?

The interventions under investigation include: Placebo (DRUG), DAS181 (DRUG), DAS181 COVID-19 (DRUG), DAS181 OL (DRUG).

Who is sponsoring clinical trial NCT03808922?

This trial is sponsored by Ansun Biopharma, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03808922 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

COVID-19

All registered trials for this condition

Lower Respiratory Tract Infection

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.